Chemokine Receptor 2 Is a Theranostic Biomarker for Abdominal Aortic Aneurysms

7Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abdominal aortic aneurysm (AAA) is a degenerative vascular disease with a high mortality upon rupture. There is no diagnosis to predict the rupture nor effective medical therapies to prevent rupture. Here we demonstrate that the C-C chemokine receptor type 2 (CCR2) is a theranostic biomarker for AAA. In rat AAA models, we determined the potential of a CCR2-targeted positron emission tomography radiotracer [64Cu]Cu-DOTA-ECL1i predicting AAA rupture. Using a CCR2 inhibitor, we observed the effective prevention of rupture in AAA rat models. In humans, CCR2 positron emission tomography showed intense radiotracer uptake along the AAA wall in patients while little signal was observed in healthy volunteers.

Cite

CITATION STYLE

APA

Elizondo-Benedetto, S., Sastriques-Dunlop, S., Detering, L., Arif, B., Heo, G. S., Sultan, D., … Liu, Y. (2025). Chemokine Receptor 2 Is a Theranostic Biomarker for Abdominal Aortic Aneurysms. JACC: Basic to Translational Science, 10(7). https://doi.org/10.1016/j.jacbts.2025.02.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free